|
|
 | |
 Pipeline | |
| Currently，Amazigh Pharma has four Innovative product pipelines AMZ001, AMZ002, AMZ003 and AMZ004 for treating atrial fibrillation, myocardial injury/heart failure, as well as pulmonary arterial hypertension and Angina/chronic myocardial ischemia
| |
 | |
 |
| Intellectual Property |
| Invention Patents Granted from United States, China, and European Union: |
| USA, No. | US7,816,400B2 | Date of Grant: Oct 19, 2010 | |
| China, No. | ZL200810092041.2 | Date of Grant: 2012.10.10 | |
| |||
| USA, No. | US9,260,461B2 | Date of Grant: Feb 16, 2016 | |
| European Union, No. | EP2902399B1 | Date of Grant: Mar 22, 2017 | |
| China, No. | ZL201810751777.X | Date of Grant: 2021. 02. 26 | |
| China, No. | ZL202211060982.4 | Date of Grant: 2024. 08. 13 | |
| |
 |
Amazigh Pharma International Scientific Publications on Class 1 Innovative Drugs |
| Back to HOME | |